Shang Hai Zheng Quan Bao·2026-01-12 18:14Core Viewpoint - WuXi AppTec Co., Ltd. is expected to achieve significant growth in its 2025 financial performance, driven by its integrated CRDMO business model and strategic focus on enhancing production capabilities and operational efficiency [2][9]. Financial Performance Forecast - The company anticipates a revenue of approximately RMB 45.46 billion for 2025, representing a year-on-year increase of about 15.84%, with revenue from continuing operations expected to grow by approximately 21.40% [5][6]. - Adjusted net profit attributable to shareholders is projected to be around RMB 14.96 billion, reflecting a year-on-year growth of approximately 41.33% [6]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be about RMB 13.24 billion, with a year-on-year increase of approximately 32.56% [6]. - The total net profit attributable to shareholders is forecasted to be around RMB 19.15 billion, showing a substantial year-on-year growth of approximately 102.65%, which includes gains from the sale of equity interests and divestitures [3][6]. - The basic earnings per share are expected to be approximately RMB 6.70, marking a year-on-year increase of about 104.27% [3][6]. Business Model and Growth Drivers - The company continues to focus on its unique "integrated, end-to-end" CRDMO business model, addressing customer needs for empowerment and expanding new capabilities while optimizing production processes [2][9]. - The growth in revenue and profit is attributed to the company's commitment to delivering new and effective drugs to global patients [9]. Non-Operating Gains - Non-operating gains are expected to significantly impact net profit, primarily from the sale of a portion of equity in WuXi XDC Cayman Inc., estimated at approximately RMB 416.09 million, and the sale of 100% equity in two other companies, expected to yield around RMB 143.38 million [10].